Clinical Trial Update: Therapy for Migraine Prevention in Children 6-11 Years of Age [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Trokendi XR (topiramate) for migraine prevention in children aged 6-11 was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Headache Disorders
• Migraine

Drugs mentioned

• TROKENDI XR (TOPIRAMATE)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Migraine Disorders, Headache Disorders | Phase 4 | Status: TERMINATED | Results posted: 2025-11-21